Heparin Dosing: Use Actual Body Weight
For standard heparin dosing in most clinical scenarios, use the patient's actual (recorded) body weight, not ideal body weight. 1, 2, 3, 2
Standard Weight-Based Dosing Protocol
The established weight-based heparin regimen for VTE treatment is 2:
- Initial bolus: 80 units/kg of actual body weight
- Continuous infusion: 18 units/kg/hour of actual body weight
- Monitor aPTT and adjust to maintain therapeutic range (1.5-2.5 times control or aPTT 60-80 seconds) 2, 3
For acute coronary syndromes, lower doses are used: 60-70 units/kg bolus (maximum 5,000 units) followed by 12-15 units/kg/hour infusion (maximum 1,000 units/hour) 2
The Obesity Exception: When to Consider Ideal Body Weight
In patients with Class 2 obesity or higher (BMI ≥35) or body weight >160 kg, consider using ideal body weight (IBW) instead of actual body weight to avoid overdosing. 4
Recent evidence demonstrates that 4:
- Conventional actual body weight-based nomograms generate overdosing in severely obese patients (reflected by supratherapeutic aPTT or anti-Xa levels)
- IBW-adjusted dosing in obese patients undergoing cardiopulmonary bypass resulted in approximately 15% lower heparin doses with better plasma concentrations within target range 4
- Overdosing increases bleeding risk and may require excessive protamine for reversal 4
Calculating Adjusted Dosing Weight for Severe Obesity
When using adjusted weight for severely obese patients, consider 5:
- Dosing weight = IBW + 0.3(ABW - IBW), or
- Dosing weight = IBW + 0.4(ABW - IBW)
For cardiopulmonary bypass specifically in obese patients, an initial bolus of 340 units/kg IBW (rather than 300 units/kg actual body weight) achieves appropriate heparin concentrations of approximately 4.5 IU/mL 6, 7
Critical Monitoring Considerations
aPTT monitoring alone is insufficient to detect heparin overdosing, particularly in obese patients. 4, 7
- The relationship between plasma heparin concentration and aPTT is not linear and follows an asymptotic regression curve 7
- In obese patients, standard actual body weight dosing can produce very high plasma heparin concentrations (5.90 vs 4.48 IU/mL in non-obese) despite similar aPTT values 7
- Consider anti-factor Xa assay monitoring (target 0.3-0.7 IU/mL for therapeutic anticoagulation) when using standard protocols in severely obese patients 1, 2
Common Pitfalls to Avoid
Do not cap maximum heparin doses in protocols - fixed maximum doses (such as 5,000 unit bolus maximum) can result in significant delays achieving therapeutic anticoagulation, particularly in larger patients 2, 5
Do not use ideal body weight routinely for all patients - the evidence for IBW-based dosing applies specifically to severely obese patients; standard actual body weight dosing remains appropriate for normal weight and Class 1 obesity patients 4, 8
Avoid intramuscular administration - use intravenous or deep subcutaneous routes only due to frequent hematoma formation with IM injection 9